Pregnancy-Adapted Algorithm Avoids Diagnostic Imaging for PE
Suspected pulmonary embolism safely ruled out in some pregnant women with diagnostic algorithm.
Pulmonary Vascular Disorders
Balloon Pulmonary Angioplasty Safely Treats CTEPH in Older Patients
Balloon pulmonary angioplasty was considered safe and effective even in patients considered “oldest-old” with chronic thromboembolic pulmonary hypertension.
Gender, Age, and Etiology Do Not Affect Response to PAH Treatment
Age, gender, and etiology significantly influence prognosis together with the recently validated simplified PAH risk table but don’t significantly influence the response to PAH-specific treatment.
Better Guidelines for Diagnosing Pulmonary Embolism During Pregnancy Needed
Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.
Heart-Lung vs Double-Lung Transplant Outcomes in Pulmonary Hypertension
Individuals with pulmonary hypertension experienced lower primary graft dysfunction following heart-lung transplantation compared with double-lung transplantation.
Pulmonary Arterial Hypertension Risk Better Predicted by REVEAL 2.0
The REVEAL 2.0 three category score was better at discriminating risks in patients with pulmonary arterial hypertension than similar tools such as COMPERA and FPHR.
Stroke Volume Response to Exercise Identifies RV Inotropic Reserve in PAH
Investigators sought to differentiate cardiac exercise responses in patients with pulmonary arterial hypertension stratified according to established measurements of disease severity.
Pulmonary Hypertension Linked to Perioperative MACE After Noncardiac Surgery
Investigators assessed the prevalence of perioperative adverse cardiovascular events after noncardiac surgery in patients with and without pulmonary hypertension.
Lesion Morphology Can Predict Balloon Pulmonary Angioplasty-Related Complications
Lesion morphology was the sole predictor of balloon pulmonary angioplasty-related complications, whereas hemodynamic parameters were not associated with the frequency of complications.
Neprilysin Inhibitors May Provide Additive Hemodynamic Effects in PAH
There may be an additive benefit to adding neprilysin inhibitors to PDE5 therapy in patients with pulmonary arterial hypertension.
Next post in Pulmonary Vasculature
